12 Analysts Have This to Say About Terns Pharma
Portfolio Pulse from Benzinga Insights
Terns Pharma (NASDAQ:TERN) has received a majority of bullish ratings from 12 analysts in the last quarter, with an average 12-month price target of $16.83, a high of $23.00, and a low of $10.00. The average price target has increased by 29.46% over the past month.
July 26, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Terns Pharma has received mostly bullish ratings from analysts, indicating a positive outlook for the stock. The average price target has also increased significantly over the past month.
The majority of analysts have given Terns Pharma a bullish rating, indicating a positive outlook for the stock. Additionally, the average price target has increased by 29.46% over the past month, suggesting that analysts believe the stock has potential for growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100